adverse events
The three-year Ubiquitous Pharmacogenomics Consortium's PREPARE study enrolled nearly 7,000 patients in seven European countries.
FDA Updates Xeloda Labeling to Make DPYD Variant Risks More Explicit
In response to a citizen petition, the FDA has added more specific language about testing patients for DPYD gene variants that place them at risk for severe treatment-related toxicities.
New IBD Adverse Drug Response Risk Gene Identified
Genome- and exome-wide association analysis on inflammatory bowel disease patients with or without thiopurine-induced myelosuppression revealed new and known risk genes.
Warfarin Bleeding Risk SNPs Identified in African Americans
A case-control GWAS of individuals of African descent led to four chromosome 6 SNPs with apparent ties to bleeding risk associated with warfarin anticoagulants.
The effort is already bearing fruit, as the team has been able to validate several variants known to be connected with adverse drug reactions.